Outcomes in Alemtuzumab-Treated Patients With Thyroid Adverse Events: 6-Year Pooled CARE-MS Data (1509)
Year: 2021
Type: article
Source: Neurology
Authors: Colin Dayan, Beatriz Lecumberri, Ilaria Muller, Sashiananthan Ganesananthan, Samuel F. Hunter, Krzysztof W. Selmaj, Hans-Peter Hartung, Eva K. Havrdova, Christopher C. LaGanke, Tjalf Ziemssen, Bart Van Wijmeersch, Sven G. Meuth, David H. Margolin, Salman Afsar, Nadia Daizadeh, Elizabeth M. Poole, Darren P. Baker, Peter A. Senior
Institutions: Cardiff University, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Advanced Neurosciences Institute, University of Warmia and Mazury in Olsztyn, Heinrich Heine University Düsseldorf, Charles University, University Hospital Carl Gustav Carus, Hasselt University, University of Münster, University Hospital Münster, Sanofi (France), University of Alberta
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3173361847
